Skip to main content
Top
Published in: Endocrine 1/2020

01-04-2020 | Type 1 Diabetes | Original Article

The expression of Tim-1 and Tim-4 molecules in regulatory T cells in type 1 diabetes

Authors: Heming Guo, Yingxiao Shen, Ying-Hong Kong, Sicheng Li, Rong Jiang, Cuiping Liu, Chen Fang, Ji Hu

Published in: Endocrine | Issue 1/2020

Login to get access

Abstract

Purpose

The TIM family comprises of eight genes in the mouse, three of which are conserved in humans (TIM-1, TIM-3, and TIM-4). Previous studies have revealed the relationships between Tim3+ Tregs and autoimmune disease. There was little study about the expression of Tim1 and Tim4 surface molecules on Tregs. We evaluated the frequency of the Tim1+Tregs and Tim4+Tregs in type 1 diabetes (T1D) in the present study.

Methods

A total of 28 patients with T1D and 14 gender-, age-, and ethnically matched healthy volunteers were recruited. PBMCs from these individuals were isolated and analyzed by flow cytometry. Splenocytes from mice were also analyzed by flow cytometry.

Results

There is no difference in the frequency of Treg cells in peripheral blood isolated from T1D patients. Tim1 on CD4+CD25+ T cells decreased significantly in PBMC of patients with T1D(1.19 ± 0.17% vs 2.78 ± 0.38%, 95% CI:0.87–2.31, P < 0.0001), while expression of Tim4 on CD4+CD25+ T cells in PBMC was less frequent in patients with T1D than healthy people(3.0 ± 0.39% vs 6.25 ± 1.08%, 95% CI:1.08–5.43, P = 0.0044). The frequencies of CD4+CD25+Tim1+ T cells and CD4+CD25+Tim4+ T cells also decreased in spleen of hyperglycemic NOD mice. There were no significant correlations between CD4+CD25+Tim1+T-cells, CD4+CD25+Tim4+T-cells and any clinical features such as age, HbA1c, Fasting C-peptide, diabetic autoantibodies, disease duration, total cholesterol, LDL, HDL, and TG.

Conclusions

It is the first report of the expression of Tim1 and Tim4 molecules on Treg cells in T1D in the present study. We also presented evidence that the frequencies of Tim1+Tregs and Tim4+Tregs decreased significantly in both type 1 diabetic patients and hyperglycemic NOD mice. However, the specific functions of Tim1+Tregs and Tim4+Tregs are still unclear.
Appendix
Available only for authorised users
Literature
1.
go back to reference Q. Tang, J.Y. Adams, C. Penaranda et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687–697 (2008)CrossRef Q. Tang, J.Y. Adams, C. Penaranda et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687–697 (2008)CrossRef
2.
go back to reference N. Marek-Trzonkowska, M. Mysliwiec, A. Dobyszuk et al. Administration of CD4+CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care. 35, 1817–1820 (2012)CrossRef N. Marek-Trzonkowska, M. Mysliwiec, A. Dobyszuk et al. Administration of CD4+CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care. 35, 1817–1820 (2012)CrossRef
3.
go back to reference N. Marek-Trzonkowska, M. Mysliwiec, A. Dobyszuk et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin. Immunol. 153, 23–30 (2014)CrossRef N. Marek-Trzonkowska, M. Mysliwiec, A. Dobyszuk et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin. Immunol. 153, 23–30 (2014)CrossRef
4.
go back to reference J.A. Bluestone, J.H. Buckner, M. Fitch et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med 7(315), 315ra189 (2015)CrossRef J.A. Bluestone, J.H. Buckner, M. Fitch et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med 7(315), 315ra189 (2015)CrossRef
5.
go back to reference W.F. Ng, P.J. Duggan, F. Ponchel et al. Human CD4+CD25+ cells: a naturally occurring population of regulatory T-cells. Blood 98, 2736–2744 (2001)CrossRef W.F. Ng, P.J. Duggan, F. Ponchel et al. Human CD4+CD25+ cells: a naturally occurring population of regulatory T-cells. Blood 98, 2736–2744 (2001)CrossRef
6.
go back to reference A.J. de Souza, J.S. Oak, R. Jordanhazy et al. T cell Ig and mucin domain-1-mediated T cell activation requires recruitment and activation of phosphoinositide 3-kinase. J. Immunol. 180, 6518–6526 (2008)CrossRef A.J. de Souza, J.S. Oak, R. Jordanhazy et al. T cell Ig and mucin domain-1-mediated T cell activation requires recruitment and activation of phosphoinositide 3-kinase. J. Immunol. 180, 6518–6526 (2008)CrossRef
7.
go back to reference J.P. Moorman, J.M. Wang, Y. Zhang et al. Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection. J. Immunol. 189, 755–766 (2012)CrossRef J.P. Moorman, J.M. Wang, Y. Zhang et al. Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection. J. Immunol. 189, 755–766 (2012)CrossRef
8.
go back to reference X. Gao, Y. Zhu, G. Li et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS ONE 7(2), e30676 (2012)CrossRef X. Gao, Y. Zhu, G. Li et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS ONE 7(2), e30676 (2012)CrossRef
9.
go back to reference H. Sun, W. Gao, W. Pan et al. Tim3+ Foxp3 + treg cells are potent inhibitors of effector T cells and are suppressed in rheumatoid arthritis. Inflammation 40(4), 1342–1350 (2017)CrossRef H. Sun, W. Gao, W. Pan et al. Tim3+ Foxp3 + treg cells are potent inhibitors of effector T cells and are suppressed in rheumatoid arthritis. Inflammation 40(4), 1342–1350 (2017)CrossRef
10.
go back to reference L. Monney, C.A. Sabatos, J.L. Gaglia et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415, 536–541 (2002)CrossRef L. Monney, C.A. Sabatos, J.L. Gaglia et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415, 536–541 (2002)CrossRef
11.
go back to reference J. Diana, Y. Simoni, L. Furio, L. Beaudoin, B. Agerberth, F. Barrat, A. Lehuen, Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat. Med. 19(1), 65–73 (2013)CrossRef J. Diana, Y. Simoni, L. Furio, L. Beaudoin, B. Agerberth, F. Barrat, A. Lehuen, Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat. Med. 19(1), 65–73 (2013)CrossRef
12.
go back to reference G. Nocentini, C. Riccardi, GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. Eur. J. Immunol. 35, 1016–1022 (2005)CrossRef G. Nocentini, C. Riccardi, GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. Eur. J. Immunol. 35, 1016–1022 (2005)CrossRef
13.
go back to reference T. So, M. Croft, Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells. J. Immunol. 179, 1427–1430 (2007)CrossRef T. So, M. Croft, Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells. J. Immunol. 179, 1427–1430 (2007)CrossRef
14.
go back to reference S.E. Umetsu, W.L. Lee, J.J. Mclntire et al. TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat. Immunol. 6, 447–454 (2005)CrossRef S.E. Umetsu, W.L. Lee, J.J. Mclntire et al. TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat. Immunol. 6, 447–454 (2005)CrossRef
15.
go back to reference J.H. Meyers, S. Chakravarti, D. Schlesinger et al. TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat. Immunol. 6(5), 455–464 (2005)CrossRef J.H. Meyers, S. Chakravarti, D. Schlesinger et al. TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat. Immunol. 6(5), 455–464 (2005)CrossRef
16.
go back to reference S. Lindley, C.M. Dayan, A. Bishop et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54(1), 92–99 (2005)CrossRef S. Lindley, C.M. Dayan, A. Bishop et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54(1), 92–99 (2005)CrossRef
17.
go back to reference S.Z. Josefowicz, L.F. Lu, A.Y. Rudensky, Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531–564 (2012)CrossRef S.Z. Josefowicz, L.F. Lu, A.Y. Rudensky, Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531–564 (2012)CrossRef
18.
go back to reference N. Degauque, C. Mariat, J. Kenny et al. Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J. Clin. Invest. 118, 735–741 (2008)CrossRef N. Degauque, C. Mariat, J. Kenny et al. Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J. Clin. Invest. 118, 735–741 (2008)CrossRef
19.
go back to reference R. Rodriguez-Manzanet, J.H. Meyers, S. Balasubramanian et al. TIM-4 ex- pressed on APCs induces T cell expansion and survival. J. Immunol. 180, 4706–4713 (2008)CrossRef R. Rodriguez-Manzanet, J.H. Meyers, S. Balasubramanian et al. TIM-4 ex- pressed on APCs induces T cell expansion and survival. J. Immunol. 180, 4706–4713 (2008)CrossRef
20.
go back to reference M. Mizui, T. Shikina, H. Arase et al. Bimodal regulation of T cell-mediated immune responses by TIM-4. Int. Immunol. 20, 695–708 (2008)CrossRef M. Mizui, T. Shikina, H. Arase et al. Bimodal regulation of T cell-mediated immune responses by TIM-4. Int. Immunol. 20, 695–708 (2008)CrossRef
Metadata
Title
The expression of Tim-1 and Tim-4 molecules in regulatory T cells in type 1 diabetes
Authors
Heming Guo
Yingxiao Shen
Ying-Hong Kong
Sicheng Li
Rong Jiang
Cuiping Liu
Chen Fang
Ji Hu
Publication date
01-04-2020
Publisher
Springer US
Keyword
Type 1 Diabetes
Published in
Endocrine / Issue 1/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-019-02173-8

Other articles of this Issue 1/2020

Endocrine 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.